Immunization

Adam J. James, PharmD, joined Drug Topics to discuss his career journey as a chain pharmacist.

Drug Topics sat down with Adam J. James, PharmD, to discuss his journey from chain pharmacist to innovation leader at Rite Aid."

After shared decision making with their community pharmacist, patients were more likely to receive an RSV vaccine.

Lauren Angelo, PharmD, MBA, discusses effective ways pharmacists can educate and encourage their communities on the importance of flu vaccination.

Ruth Carrico, PhD, DNP, APRN, sat down with Drug Topics to discuss the importance of COVID-19 and influenza vaccination.

Ruth Carrico, PhD, DNP, APRN, discussed declining influenza and COVID-19 vaccination rates and how it has created a looming threat for public health officials.

Ruth Carrico, PhD, DNP, APRN, discussed the importance of annual vaccination and overall health awareness and literacy during the winter flu season.

Before marketing your pharmacy’s immunizations services, check out these takeaways from NCPA.

A second immunization session focused on updates in meningococcal disease, HPV, and Mpox.

The first of a 2-part presentation focused on vaccines for COVID-19, flu, RSV, and pneumococcal disease.

As the H5 bird flu outbreak gradually impacts human health in the US, health care experts weighed in on possibilities of a future vaccine.

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

The new recommendations suggest vaccination at age 50, rather than age 65.

Abrysvo is the only RSV vaccine approved for use in this age group.

Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.

Pharmacist education can positively impact patient counseling around vaccinations in older adults.

Vaccination against HPV can prevent thousands of cases of cancer each year.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

Cases of meningococcal disease currently exceed prepandemic levels.

Dozens of presentations at IDWeek 2024 focused on available immunizations, such as those for COVID-19, respiratory syncytial virus, and flu.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.

The pilot Will Evaluate Measure Concepts and Data Exchange in Value-Based Arrangements.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

The National Foundation for Infectious Diseases released a survey regarding the feelings of US adults toward influenza, COVID-19, RSV, and pneumococcal disease.